Genotyping analysis in patient-derived MFS primary cultures demonstrated the promising role of surface glycoprotein CD109, a negative regulator of transforming growth factor-beta (TGF-β) pathway in the differential diagnosis of more aggressive high-grade myxofibrosarcoma identifying this marker as a possible therapeutic target (44). The gene discussed is TGFB1; the disease is myxofibrosarcoma.